Abstract: P6586

Brugada syndrome risk stratification - Evaluation of clinical and ecg risk markers in a multicenter international primary prevention cohort.

Authors:
S Honarbakhsh1, R Providencia1, J Garcia-Hernandez2, CA Martin3, RJ Hunter1, WY Lim1, C Kirkby1, A Sharifzadehgan4, C Waldmann4, E Marijon4, C Munoz-Esparza5, J Lacunza5, JR Gimeno-Blanes5, PD Lambiase1, BS The Brugada Syndrome Risk Investigators1, 1Barts Health NHS Trust, Electrophysiology - London - United Kingdom of Great Britain & Northern Ireland, 2University College London, Farr Research Institute - London - United Kingdom of Great Britain & Northern Ireland, 3Papworth Hospital NHS Trust, Electrophysiology - Cambridge - United Kingdom of Great Britain & Northern Ireland, 4European Hospital Georges Pompidou, Electrophysiology - Paris - France, 5Hospital Clíñico Universitario Virgen de la Arrixaca, Electrophysiology - Murcia - Spain,

On behalf: The Brugada Syndrome Risk Investigators

Topic(s):
Brugada Syndrome

Citation:
Background- Risk stratification for sudden cardiac death (SCD) in Brugada syndrome (BrS) is a significant challenge.

Purpose- To evaluate the importance of clinical and ECG factors in the likelihood of developing significant ventricular arrhythmias (VAs)/SCD in BrS patients.

Methods- VA occurrence during follow-up were assessed and the role of 16 proposed clinical or ECG risk markers evaluated in a multicenter international study of BrS patients and no history of cardiac arrest. Markers with predictive power were identified and incorporated into a risk score model.

Results- Across 15 international centers, 1084 patients were included. During a follow-up of 5.3 years (IQR 2.7-9.0 years) 110 patients had VA occurrence (10.1%) with an annual event rate of 1.7% (95%CI 1.4-2.0). Of the 16 proposed risk factors, diagnosis by family screening of sudden cardiac death (HR 4.65; p<0.001), probable arrhythmia related syncope (HR 3.88, p<0.001), type 1 spontaneous ECG (HR 3.56; p<0.001), Early Repolarisation (HR 3.15; p<0.001) and type 1 Brugada pattern in peripheral leads (HR 2.42; p<0.001) were associated with a higher VA occurrence risk during follow-up. These 5 variables were incorporated into a risk score model whereby each variable was allocated a point score based on the variable's predictive strength. The total points obtained from the model for a patient could then be translated into the predicted VA occurrence risk during follow-up (Figure 1). The model showed a sensitivity of 63.5% (95%CI 50.0-76.9) and specificity of 84.2% (95%CI 81.1-87.1) in predicting VA occurrence at 5-years follow-up. The model showed a greater discriminative power compared to an existing model (AUC 0.83 vs. 0.71; p<0.001).

Conclusions- This multicenter study with longest reported follow-up to date identified 5 risk markers for VA occurrence. Utilizing these markers in a risk score model can aid BrS risk stratification to enable individualized risk prediction and ICD prescription.
Background - Risk stratification for sudden cardiac death (SCD) in Brugada syndrome (BrS) is a significant challenge.

Purpose - To evaluate the importance of clinical and ECG factors in the likelihood of developing significant ventricular arrhythmias (VAs)/SCD in BrS patients.

Methods - VA occurrence during follow-up were assessed and the role of 16 proposed clinical or ECG risk markers evaluated in a multicenter international study of BrS patients and no history of cardiac arrest. Markers with predictive power were identified and incorporated into a risk score model.

Results - Across 15 international centers, 1084 patients were included. During a follow-up of 5.3 years (IQR 2.7–9.0 years) - 110 patients had VA occurrence (10.1%) with an annual event rate of 1.7% (95%CI 1.4–2.0).

Of the 16 proposed risk factors, diagnosis by family screening of sudden cardiac death (HR 4.65; p<0.001), probable arrhythmia related syncope (HR 3.88, p<0.001), type 1 spontaneous ECG (HR 3.56; p<0.001), Early Repolarisation (HR 3.15; p<0.001) and type 1 Brugada pattern in peripheral leads (HR 2.42; p<0.001) were associated with a higher VA occurrence risk during follow-up. These 5 variables were incorporated into a risk score model where each variable was allocated a point score based on the variable's predictive strength.

The total points obtained from the model for a patient could then be translated into the predicted VA occurrence risk during follow-up (Figure 1). The model showed a sensitivity of 63.5% (95%CI 50.0–76.9) and specificity of 84.2% (95%CI 81.1–87.1) in predicting VA occurrence at 5-year follow-up. The model showed a greater discriminative power compared to an existing model (AUC 0.83 vs. 0.71; p<0.001).

Conclusions - This multicenter study with longest reported follow-up to date identified 5 risk markers for VA occurrence. Utilizing these markers in a risk score model can aid BrS risk stratification to enable individualized risk prediction and ICD prescription.